NEW YORK, NY--(Marketwire - Mar 13, 2013) - Blue chips have garnered increased attention from investors in 2013 as the Dow Jones Industrial Average have hovering near an all-time high. Last week, the Dow Jones Industrial Average closed at 14253.77, topping its previous high of 14164.53, which was set in October 2007. Research Driven Investing examines investing opportunities in Blue Chips and provides equity research on Johnson & Johnson (
Access to the full company reports can be found at:
Dividend payments from Dow Jones Industrial Average constituents have experienced a steady rebound since falling sharply during the financial crisis. Trailing 12-month dividends per share for the 30 companies that make up the Dow was a combined $348.61 as of the end of January. The total was the highest level seen since January 2008, and just short of the all-time high of $372.46 set in May 2007, according to FactSet. Data from FactSet showed blue chips held roughly $487.9 billion in cash at the end of 2012, an increase of 70 percent when compared to the end of 2008.
"When you look at the overall dividends, yes, they're [near] all-time highs. But the ability for companies to increase dividends from here remains very strong," said Dreyfus Corp.'s Chief Investment Officer, Chris Sheldon.
Research Driven Investing releases regular market updates on Blue Chips so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and industry newsletters.
Johnson & Johnson currently offers investors an annual dividend of $2.44 a share, for a dividend yield of approximately 3.11 percent. Shares of the company have gained roughly 12 percent year-to-date. For the fourth quarter of 2012, Johnson & Johnson reported sales of $17.6 billion, a year-over-year increase of 8 percent.
Merck currently offers investors an annual dividend of $1.72 a share, for a dividend yield of approximately 3.82 percent. Shares of the company have surged roughly 10 percent year-to-date. Merck has announced that Data Safety Monitoring Board (DSMB) of the IMPROVE-IT trial has recommended the trial continue.
Research Driven Investing has not been compensated by any of the above-mentioned publicly traded companies. Research Driven Investing is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: